Anagenics Limited · ASX:AN1
Anagenics — Cellmid — Investor Presentation (July 2018)
30 slides from Anagenics's investor presentation, July 2018

Slide 1: Investor Presentation July 2018
For personal use only INVESTOR PRESENTATION CEO Maria Halasz JULY 2018 ASX: CDY

Slide 2: Focused on scaling multi-channel distribution of clinically proven products
For personal use only Focused on rapidly scaling the multi- channel distribution of flagship, clinically proven product ranges in Asia, USA and Australia. Continue to extract value from midkine drug development and patent portfolio “I feel younger, you know, like in my 30’s” 2

Slide 3: Company Overview
COMPANY OVERVIEW Cellmid has three wholly owned subsidiaries operating in two distinct business segments. For personal use only CONSUMER HEALTH PRE-CLINICAL THERAPEUTIC ASSETS ADVANGEN Anti-aging functional cosmetics and consumer health products for hair, face and wellbeing. Product range includes a

Slide 4: Investment Highlights
INVESTMENT HIGHLIGHTS For personal use only Highly experienced Existing distribution Proprietary, Exposure to the fast Near term growth Midkine drug board and networks in clinically validated growth anti-aging via new product portfolio management team Australia, Japan, products that segment of the r

Slide 5: A Strong Board
A STRONG BOARD A vibrant mix of global retail, life sciences and finance experience For personal use only Dr David King | Chairman Maria Halasz | CEO and Managing Director GOVERNANCE ENTREPRENEURSHIP LIFE SCIENCES RETAIL FINANCE ENTREPRENEURSHIP An experienced independent chairman with expertise in

Slide 6: Advangen
For personal use only ADVANGEN Positive Aging 6

Slide 7: What is evolis?
WHAT IS ? is a clinically validated, TGA listed portfolio of haircare For personal use only treatment products specifically formulated as an anti-aging hair solution, combining science and nature to bring back your best hair. is the culmination of over 10 years of dedicated research into hair growth

Slide 8: Addressing a Global Hair Growth Problem
ADDRESSING A GLOBAL HAIR GROWTH PROBLEM USA For personal use only 18 million men and women are suffering from hair loss in the US PRODUCT RANGE • 13% of women experience hair loss by 40 increasing up to 50% by age 70 and • 50% of men experience significant hair loss by age 50 PROFESSIONAL Reverse, P

Slide 9: How Does evolis Work?
HOW DOES WORK ? • FGF5 is a naturally occurring protein and critical in the hair cycle For personal use only • Its role is to signal hair to stop growing • Blocking FGF5 can extend the growth phase of hair resulting in increased hair growth, reduced hair loss and longer, stronger and thicker hair •

Slide 10: Market Opportunity
MARKET OPPORTUNITY ANTI-AGING For personal use only GLOBAL HAIRCARE HAIRLOSS forecast to grow MARKET 24% Forecasted to reach 2018-2022 with emerging US$11.8B markets expected to generate double digit growth3 by 2024 1 GLOBAL HAIRCARE MARKET outperformed fast is estimated to be growing anti-aging hai

Slide 11: Competitive Landscape
COMPETITIVE LANDSCAPE évolis® is the only anti-aging haircare product that is based évolis® ticks all the boxes For personal use only on natural ingredients, clinically and scientifically validated and effective in reducing hair loss and increasing hair growth évolis® vs. other anti-aging brands2. é

Slide 12: What is Fillerina?
WHAT IS FILLERINA® ? Fillerina® is the first non-injectable transdermal filler For personal use only that has been clinically validated to reduce wrinkles and increase facial volume. The Fillerina® treatment combines six hyaluronic acids to facilitate the filling in and plumping up of tissues. In De

Slide 13: The Distribution Agreement
THE DISTRIBUTION AGREEMENT For personal use only • Advangen has entered into an agreement with Labo WHY FILLERINA® ? International to undertake the exclusive distribution of Fillerina® in AU & NZ (launch September 2018) • First in class, best in class non-injectable • Second product within Advangen

Slide 14: Strong Revenue Growth in Advangen to Date
STRONG REVENUE GROWTH IN ADVANGEN TO DATE, FY2019 EXPECTED TO BE A BREAKOUT YEAR Q1-Q3 FY2018 revenue has already exceeded total revenue for FY2017 For personal use only Acquired in 2013 from Japanese owners with revenues increasing Advangen revenue 4X since acquisition, CAGR of 57% over period FY14

Slide 15: Growth Drivers
GROWTH DRIVERS Growth is expected to come from four broad categories: New products For personal use only • Extension of the product range (new products, refer to right) Revive & Lift Spray • Distribution channel expansion in existing markets Non-comedogenic dry • Geographical expansion within USA, C

Slide 16: Australia
AUSTRALIA For personal use only Existing Channels • E-commerce: Dedicated global website launched in April 2018, including the AU portal • Pharmacy: évolis® products are stocked in over 1,800 pharmacies (up from 1,000 in FY2017) accounting for around 35% of the market • Servicing selected premium sa

Slide 17: Japan
JAPAN Existing Channels HIGHLIGHTS For personal use only • QVC TV shopping: Continue to market through television shopping channel QVC Japan, providing exposure to 26 million households. QVC Japan accounts for 65% of Japanese revenue. • Barbershops: Service barbershop network via Japan’s largest who

Slide 18: USA
USA HIGHLIGHTS For personal use only Existing Channels • E-commerce: Currently limited activity (to increase after the launch of fully operational website) • Premium retail: Partnerships entered into with Neiman Marcus started in September 2017, Soft Surroundings in April 2018 and Bloomingdales will

Slide 19: China
CHINA Existing and near term channels For personal use only • Distribution agreement: Exclusive five-year agreement signed in May 2018 with Fukangren Bio- Pharm Tech. Co. Ltd for the distribution of évolis® lotions and shampoos to over 500 pharmacies, associated hospitals and clinics in China. The a

Slide 20: Business Performance & Outlook
For personal use only BUSINESS PERFORMANCE & OUTLOOK 20

Slide 21: Financial Performance
FINANCIAL PERFORMANCE For personal use only 6 Months Ended 31 Dec H1 2018 H1 2017 (A$’Ms) (A$’Ms) % chg Q3 2018 Quarterly Update Consumer health revenue 3.1 2.0 50.3% • Record receipts from customers of Midkine & license revenue 0.1 0.1 (1.3)% $2.2 million, an increase of 81% in Other income 1.0 0.8

Slide 22: Anticipated Newsflow
ANTICIPATED NEWSFLOW Record $2 million China distribution For personal use only Tokyo concept store consumer health agreement launch sales $ Fillerina Targeted Cellmid news flow: Placement to Dennis agreement .60 Eck • Launch of new global website • New product launches .40 • Additional retail partn

Slide 23: Lyramid & Kinera: Midkine in Therapy
For personal use only Lyramid & Kinera Midkine in therapy 23

Slide 24: Midkine – A Novel and Compelling Target
MIDKINE – A NOVEL AND COMPELLING TARET Discovered in 1988, midkine is the subject of over 815 publications (300+ in oncology) For personal use only • CDY has the largest portfolio of midkine IP assets globally with several Midkine Overexpression relative to healthy tissue Tissue Blood Urine potentia

Slide 25: Lyramid and Kinera
LYRAMID KINERA • Stage: pre-clinical • Stage: pre-clinical • Drug class: Antibodies CAB101 and CAB102 (cancer, fibrosis, • Drug class: Protein, MK For personal use only chronic kidney disease, myocarditis) and companion diagnostic • Applications: heart failure, chronic heart conditions and ischemia

Slide 26: Objectives for Lyramid & Kinera in 2018
OBJECTIVES FOR LYRAMID & KINERA IN 2018 For personal use only Complete pre-clinical studies to enter clinical development • Clinical indications will be assessed on the strength of pre-clinical evidence during 2018 • Focused on capital preservation - partnerships are the preferred strategic approach

Slide 27: Appendices
For personal use only APPENDICES 27

Slide 28: Who are QVC?
WHO ARE QVC? For personal use only QVC is a multiplatform shopping experience engaging millions QVC Global Scale of shoppers with hundreds of brands globally through online, Country TV Homes Channels broadcasting, mobile and social channels. (Millions) United States 104 3 The QVC business model allo

Slide 29: FGF5 and evolis Publications in Peer Reviewed Journals
FGF5 AND EVOLIS PUBLICATIONS IN PEER REVIEWED JOURNALS – SCIENTIFIC AND CLINICAL VALIDATION For personal use only • Maeda T., Yamamoto T., Isikawa Y. Sanguisorba Officinalis Root Extract has FGF5 Inhibitory activity and reduces hair loss by causing prolongation of the anagen period. Skin research an

Slide 30: Disclaimer
For personal use only DISCLAIMER Forward looking statements This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially di
Source: Internet Archive copy of anagenics.com
More decks from Anagenics Limited
H1 2026 Earnings Presentation12 slides · Feb 25, 2026
Shareholder Meeting (November 2025)14 slides · Nov 25, 2025
FY2025 Earnings Presentation15 slides · Aug 28, 2025
Q3 2025 Earnings Presentation15 slides · May 5, 2025
Shareholder Meeting (November 2024)12 slides · Nov 26, 2024
FY2024 Earnings Presentation14 slides · September 2024